DOCKET NO.: C1039-7

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant:

Serial No.:

09/672,126

Confirmation No.:

6887

Filed:

September 27, 2000

For:

METHODS RELATED TO IMMUNOSTIMULATORY

NUCLEIC ACID-INDUCED INTERFERON

Examiner:

Nguyen, Q.

Art Unit:

1636

## CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 10 day of December, 2003.

Alan W. Steele, M.D., Ph.D., Reg. No. 45,128

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

Supplemental Information Disclosure Statement Under 37 C.F.R. §1.56, 1.97 & 1.98 [X]

[X]Form PTO-1449 with References Cited

Check in the amount of \$180.00 [X]

[X]Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617)720-3500, Boston, Massachusetts.

The Commissioner is hereby authorized to charge any deficit or credit any overpayment to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

Hartmann et al., Applicant

By:

Alan W. Steele, M.D., Ph.D., Reg. No. 45,128

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2211

Telephone: (617) 720-3500

Docket No.: C1039.70044US00 Date: December 10, 2003

**xNDD**x



DOCKET NO.: C1039.70044US00

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Hartmann et al.

Serial No.:

09/672,126

Confirmation No.:

6887

Filed:

September 27, 2000

For:

METHODS RELATED TO IMMUNOSTIMULATORY

NUCLEIC ACID-INDUCED INTERFERON

Examiner:

Nguyen, Q.

Art Unit:

1636

#### CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 10th day of December, 2003.

Alan W. Steele, M.D., Ph.D., Reg. No. 45,128

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# SUPPLEMENTAL STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 C.F.R. §§ 1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

# PART I: Compliance with 37 C.F.R. § 1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution in this application.

The fee as set forth in 37 C.F.R. § 1.17(p) is enclosed.

12/17/2003 ZJUHAR1 00000046 09672126

01 FC:1806

180.00 OP

Art Unit: 1636

3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. § 102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted, Hartmann et al., *Applicant* 

By:

Alan W. Steele, M.D., Ph.D., Reg. No. 45,128

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2211

Telephone: (617) 720-3500

Docket No. C1039.70044US00 Date: December 10, 2003

XNDDX

PPLICATION NO.: 09/672,126	ATTY. DOCKET NO.: C1039.70044US00
LING DATE: September 27, 2000	CONFIRMATION NO.: 6887
APPLICANT: Hartmann et al.	
GROUP ART UNIT: 1636	EXAMINER: Nguyen, Q.
	APPLICANT: Hartmann et al.

U.S. PATENT DOCUMENTS

Lixaminot 5	Cite	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication or of issue of Cited Document	
	No.	Number	Kind Code	Document	MM-DD-YYYY	
	A21	2003/0055014	A1	Bratzler	03-20-2002	
	A22	2002/0091097	A1	Bratzler et al.	07-11-2002	
	A23	2002/0164341	A1	Davis et al.	11-07-2002	
	A24	2002/0165178	A1	Schetter et al.	11-07-2002	
	A25	2002/0198165	A1	Bratzler et al.	12-26-2002	
	A26	2003/0026801	A1	Weiner et al.	02-06-2003	
	A27	2003/0050261	Al	Krieg et al.	03-13-2003	
	A28	2003/0050263	A1	Krieg et al.	03-13-2003	
	A29	2003/0050268	A1	Krieg et al.	03-13-2003	
	A30	2003/0091599	Al	Davis et al.	05-15-2003	
	A31	2003/0100527	Al	Krieg et al.	05-29-2003	
	A32	2003/0104523	A1	Lipford et al.	06-05-2003	
	A33	2003/0139364	A1	Krieg et al.	07-24-2003	
·	A34	2003/0148976	A1	Krieg et al.	08-07-2003	
	A35	2003/0148316	A1	Lipford et al.	08-07-2003	
	A36	2003/0166001	A1	Lipford	09-04-2003	
	A37	2003/0181406	A1	Schetter et al.	09-25-2003	
	A38	2003/0191079	A1	Krieg et al.	10-09-2003	

FOREIGN PATENT DOCUMENTS

Examiner's Cite No.	Cite	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of	Translation
	No.	Office/ Country	Number	Kind Code	(not necessary)	Cited Document MM-DD-YYYY	(Y/N)
	B32	WO	02/069369	A2		09-06-2002	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's	Cite	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item	Translation
Initials	No	(book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s),	(Ÿ/N)
IIIIIIII		publisher, city and/or country where published.	
	C146	LEE SW et al., Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials. <i>J Immunol</i> . 2000 Oct 1;165(7):3631-9.	
C147	VERTHELYI D et al., Human peripheral blood cells differentially recognize and respond to two		
	0	distinct CpG motifs. J Immunol. 2001 Feb 15;166(4):2372-7.	

EVAMINED	DATE CONSIDERED
EXAMINER	DATE CONSIDERED
!	
!	
i l	

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>\*</sup>a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

## PART II: Information Cited

A. The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

B. The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications (copies enclosed) that may contain subject matter related to this application:

Docket No.	Serial No.	Filing Date	Inventor
C1041.70002US00	09/241,653	02-02-1999	Wagner et al.
C1040.70006US00	09/316,199	05-21-1999	McCluskie et al.
C1041.70005US00	09/355,254	02-22-2000	Wagner et al.
C1041.70010US00	09/786,436	03-02-2001	Wagner et al.
C1039.70057US00	09/965,101	09-26-2001	Davis et al.
C1039.70062US00	10/187,489	07-02-2002	Krieg et al.
C1039.70069US00	10/314,578	12-09-2002	Krieg et al.
C1041.70035US00	10/373,381	02-25-2003	Wagner et al.
C1039.70070US00	10/382,822	03-06-2003	Krieg et al.
C1041.70037US00	10/407,952	04-04-2003	Lipford et al.
C1039.70072US00	10/434,696	05-09-2003	Davis et al.
C1039.70071US00	10/435,656	05-09-2003	Krieg et al.
C1039.70075US00	10/613,916	07-03-2003	Krieg et al.
C1039.70077US00	10/619,279	07-14-2003	Krieg
C1039.70078US00	10/627,331	07-25-2003	Krieg et al.
C1039.70079US00	10/627,413	07-25-2003	Krieg et al.

# PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

- 1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- 2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;